ARTICLE | Company News
Aveo Pharmaceuticals, Merck deal
October 4, 2010 7:00 AM UTC
Merck terminated a 2007 deal and returned worldwide rights to Aveo for cancer candidate AV-299 ( SCH 900105). Merck, which gained rights to AV-299 through its acquisition of Schering-Plough Corp., s...